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1. Introduction 
A wide variety of bacteria and fungi are found on the human skin. Although some skin 
microorganisms produce antibacterial peptides that inhibit invasion by pathogens or 
promote the integrity of cutaneous defenses by eliciting host immune responses, the normal 
microbiome can also cause several skin diseases. 
Atopic dermatitis (AD) is a chronic disease that causes pruritus and involves cycles of 
remission and deterioration. AD is the result of dry hypersensitive skin. When the skin is 
dry, the protective barrier function of the cutaneous surface horny layer is compromised, 
and the skin readily develops dermatitis in response to various external stimuli, including 
skin microorganisms. Serum from almost all AD patients contains IgE antibodies against 
some skin microorganisms. For example, staphylococcal superantigen-specific IgE is present 
in the serum of AD patients, but not in the serum of healthy individuals. Normally, the 
weakly acidic condition of healthy skin prevents colonization by Staphylococcus aureus. 
However, in patients with AD, the skin pH is shifted toward neutrality, allowing S. aureus to 
grow and exacerbate AD. 
In the cutaneous fungal microbiome, lipophilic yeasts of the genus Malassezia are the 
predominant species on human skin. As Malassezia species require lipids for growth, they 
preferentially colonize sebum-rich areas such as the head, face, and neck, as opposed to the 
limbs or trunk. Specific IgE antibody against Malassezia species is found in the serum of AD 
patients. Antifungal therapy improves the symptoms of AD by decreasing the level of 
Malassezia colonization, suggesting that these microorganisms also exacerbate AD. 
Malassezia species, unlike S. aureus, colonize both AD patients and healthy subjects. 
Currently, the genus Malassezia consists of 14 species. Of these, M. globosa and M. restricta 
have been detected in almost all AD patients, suggesting that these two Malassezia species 
play a significant role in AD. The level of specific IgE antibody against both species is 
greater than that against other Malassezia species. 
This chapter discusses cutaneous fungi as an exacerbating factor in AD, focusing on: 
- the fungal microbiome in patients with AD. 
- immunological aspects of fungal colonization, and 
- treatment with antifungal agents. 
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2. The fungal microbiome in patients with atopic dermatitis 
2.1 Colonization by the fungus Malassezia in patients with atopic dermatitis 
The lipophilic yeast Malassezia is the predominant fungus on human skin. Morphologically, 
these microorganisms are ovoid, elongate, and cylindrical (Fig. 1). Their genome is smaller 
than that of other fungi (Xu et al. 2007). As Malassezia species require lipids for growth, they 
preferentially colonize sebum-rich areas such as the head, face, or neck, rather than the 
limbs or trunk. Specific IgE antibodies against Malassezia are present in the serum of patients 
with AD, and antifungal therapy can improve the symptoms of AD by decreasing the 
degree of colonization by Malassezia; thus, this fungus is believed to be an exacerbating 
factor in AD (more details are provided in a later chapter). In contrast to S. aureus, Malassezia 
species colonize both AD patients and healthy individuals. In addition to AD, Malassezia 
species are responsible for seborrheic dermatitis, folliculitis, and ptiryasis versicolor (Gupta 
et al. 2004; Ashbee 2007). Currently, 14 species are recognized within the genus Malassezia 
(Table 1), and five of these (M. caprae, M. cuniculi, M. equina, M. nana, and M. pachydermatis) 
show affinity for nonhuman animals. 
 
Host Species 
Species implicated in skin 
disease in human 
Human associated species Malassezia dermatis AD 
 Malassezia furfur SI 
 Malassezia globosa AD, SD, PV 
 Malassezia japonica  
 Malassezia obtusa  
 Malassezia slooffiae   
 Malassezia sympodialis AD, SD 
 Malassezia restricta AD, SD, PV 
 Malassezia yamatoensis  
Nonhuman animal associated 
species 
Malassezia caprae  
 Malassezia cuniculi  
 Malassezia equina  
 Malassezia nana  
 
Malassezia 
pachydermatis 
 
AD, atopic dermatitis; SD, seborrheic dermatitis; SI, systemic infection; PV, pityriasis versicolor 
Table 1. Currently accepted Malassezia species 
A number of epidemiological studies have been conducted during the past decade to 
elucidate the role of Malassezia as an exacerbating factor in AD. The first was carried out by 
Nakabayashi et al. (2000) in Japan and detected M. furfur, M. globosa, M. sympodialis, and M. 
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slooffiae in 21.4, 14.3, 7.1, and 3.6% of samples from Japanese AD patients, respectively. A 
study conducted in Sweden in 2005 produced similar results (Sandström et al. 2005). 
However, a Canadian study by Gupta et al. (2001) reported the predominant species to be M. 
sympodialis, which was detected in 51.3% of the samples from AD patients. All of these 
studies were performed using culture-dependent methods. In all cases, scale samples were 
collected by an appropriate method, e.g., swabbing, scratching, or stripping, and were 
incubated in medium containing several types of fatty acids. The recovered microorganisms 
were identified based on biochemical or physiological characteristics, including assimilation 
of Tween compounds and esculin, catalase reaction, and maximum growth temperature 
(Guého-Kellermann 2010; Kaneko et al. 2007). However, culture-dependent methods may 
not provide accurate and reliable results for Malassezia. The efficiency of culturing Malassezia 
strains depends on the isolation medium used, and the growth of some species, such M. 
obtusa and M. restricta, is slower than that of others. 
 
 
Magnification is x5,000. 
Fig. 1. Morphology of Malassezia restricta by scanning electron microscope  
To overcome the difficulties of culture-dependent methods, including scale sampling 
methods, culturing conditions, and isolation techniques, Sugita et al. (2001) developed the 
first molecular analytical method for Malassezia. For this method, scale samples are 
collected by stripping with medical transparent dressing, and skin Malassezia DNA is 
directly extracted from the dressing. The Malassezia microbiota is then analyzed by real-
time PCR, specific detection by PCR with a species-specific primer, or an rRNA clone 
method (Sugita et al. 2011). Although more expensive than culture-dependent methods, a 
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molecular-based, non-culture approach appears to be the most reliable and appropriate 
for analysis of the skin Malassezia microbiota (Sugita et al. 2001; Morishita et al. 2006; 
Takahata et al. 2007a, 2007b; Tajima et al. 2008; Amaya et al. 2007). In all scale samples 
from AD patients, both M. globosa and M. restricta were detected by the molecular-based 
method, with the level of colonization by M. restricta being approximately 1.6 times that of 
M. globosa (Sugita et al. 2006a). Malassezia sympodialis was the second most predominant 
species (detected in 58% of the cases), and M. dermatitis, M. furfur, M. obtusa, and M. 
slooffiae were detected in less than 30% of the cases (Fig. 2). These results suggest that both 
M. globosa and M. restricta may significantly exacerbate AD. 
 
 
Malassezia DNA was detected by nested PCR assay with species-specific primers 
Fig. 2. Colonization frequency of Malassezia in the scale of patient with atopic dermatitis 
Given that M. globosa and M. restricta commonly colonize both AD patients and healthy 
individuals, specific genotypes of these microorganisms may play a role in AD (Sugita et al. 
2003, 2004, 2010). The fungal rRNA gene consists of four subunits: 5S, 5.8S, 18S (small), and 26S 
(large). Located between the subunits are an internal transcribed spacer (ITS) and an intergenic 
spacer (IGS). In M. globosa, the IGS is 444 to 454 bp long and has four short sequence repeats 
(SSRs), (CT1)n, (CT2)n, (CT3)n, and (GT)n, which occur at positions 29–49, 278–291, 380–485, 
and 242–267, respectively, in the IGS sequence of M. globosa strain CBS 7996. Alignments of 
IGS 1 sequences of two M. globosa strains are shown in Fig. 3. The number of (CT)n SSRs in the 
IGS 1 region is more variable in samples from healthy individuals than in those from AD 
patients. In samples from AD patients, the number of sequence repeats in the IGS 1 region 
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ranged from 4 to 11 for (CT1)n, 3 to 10 for (CT2)n, and 3 to 11 for (CT3)n, with 4 (CT1)n repeats 
in 50% of the samples, 8 (CT2)n in 60%, and 9–11 (CT3)n in 80%. For (GT)n, the respective 
numbers of repeats in 70–80% of the SSRs in the IGS 1 region were 9–11 in samples from AD 
patients and 15–19 in samples from healthy individuals. A phylogenetic tree constructed from 
52 IGS 1 sequences is shown in Fig. 4. The tree consists of four major groups, which 
correspond to the sources of the samples (AD patients or healthy individuals). Two groups are 
from AD patients, and one is from healthy individuals. The remaining group included 
samples from both AD patients and healthy individuals. The IGS 1 sequences were more 
diverse in the samples from healthy individuals compared with AD patients. The IGS 1 
sequence similarity was 94.5 ± 3.5% among the AD patient samples and 89.9 ± 3.5% among the 
samples from healthy individuals. The IGS 1 sequences of M. restricta are divided into two 
major groups, corresponding to AD patients and healthy individuals. 
 
 
Fig. 3. DNA sequences of the IGS 1 region of M. globosa. 
2.2 Malassezia colonization and severity of AD  
The Malassezia microbiota of the skin is also associated with the severity of AD. Fifty-six 
adult neck and head AD patients (21 mild, 18 moderate, and 17 severe cases) and 32 healthy 
individuals were examined for skin Malassezia microbiota, using a real-time PCR assay 
(Kaga et al. 2011). The level of colonization by Malassezia was almost identical among the 
mild and moderate AD patients and the healthy individuals, while Malassezia colonization 
in the severe AD cases was approximately 2- to 5-fold that in the mild and moderate AD 
patients and healthy individuals (Fig. 5A). Two major species, M. globosa and M. restricta, 
accounted for more than 80% of all Malassezia colonization in AD patients of all severities, 
but their proportions differed with severity. In the mild and moderate cases, M. restricta 
predominated over M. globosa (p < 0.05), whereas the proportions of M. globosa and M. 
restricta were almost identical (p > 0.05) in the severe patients (Fig. 5B). 
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AD, patients with atopic dermatitis; HS, healthy subjects. 
Fig. 4. Phylogenetic tree of M. globosa colonizing the skin surface of AD patients and healthy 
subjects based on DNA sequences of the IGS 1 region 
 
 
Fig. 5. Level of Malassezia colonization in patients with atopic dermatitis and in healthy 
individuals (A). Ratio of the two major Malassezia species, M. globosa and M. restricta, in 
patients with atopic dermatitis and in healthy individuals (B) 
In a comprehensive analysis using an rRNA gene clone library method, Zhang et al. (2011) 
found that not only Malassezia but also the overall fungal microbiota differed according to 
AD severity. Their analysis of 3,647 clones of the fungal rRNA gene in scale samples from 
nine AD patients (3 mild, 3 moderate, and 3 severe cases) and 10 healthy individuals 
revealed 58 fungi and seven unknown phylotypes. Malassezia predominated, representing 
63–86% of the clones identified from each subject. The number of clones had no noticeable 
relationship to disease severity, with the mild, moderate, and severe cases accounting for 
67.8 ± 2.2, 70.7 ± 2.8, and 64.9 ± 1.8% of the clones, respectively. The study also confirmed 
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that both M. globosa and M. restricta were the predominant species regardless of disease 
severity, with a detection rate of 57.5–70.4% in all clones analyzed. However, the ratio of M. 
globosa to M. restricta in the mild and moderate cases (M. restricta/M. globosa: 3.1–3.4 in mild 
and 2.1–4.1 in moderate cases) differed from that in the severe cases (1.1–1.4). Figure 6 
shows the phylogenetic distribution between AD patients and healthy individuals, based on 
principal coordinates analysis. Patients with mild or moderate symptoms of AD constituted 
a single cluster, and patients with severe disease formed a separate cluster. Similarly, the 
healthy individuals clustered independently. 
 
 
Closed triangle, patients with mild symptoms; closed square, patient with moderate symptoms; closed 
circle, patients with severe symptoms; open circle, healthy individuals 
Fig. 6. Principal coordinates analysis (PCA) score plot of the sequence profiles for the 
predominant skin fungi 
Differences in microbiota are thought to be attributable to differences in the physiological 
condition of the skin between patients with AD and healthy subjects. For example, skin pH 
may change skin microbiota (Seidenari and Giusti, 1995). Staphylococcus epidermidis is 
present in the skin microbiota of healthy individuals, whereas S. aureus is not. The level of 
colonization by S. aureus increases according to the severity of AD. In contrast, the level of 
colonization by S. epidermidis decreases gradually with increasing AD severity. Healthy skin 
is weakly acidic, whereas the skin pH in patients with AD is near neutral, which facilitates 
invasion by exogenous microorganisms, including S. aureus (Higaki et al. 1999; Hoeger et al. 
1992). The expression levels of antimicrobial peptides may also affect the fungal microbiota 
(Howell 2007). The antimicrobial peptides known as defensins and cathelicidins are 
deficient in the skin of AD patients, and thus the fungal microbiota should be different 
between AD patients and healthy individuals. Sebum is a growth medium for skin 
microorganisms and consists of squalene, cholesterol esters, wax esters, triglycerides, free 
fatty acids, cholesterol, ceramides, cholesterol sulfate, and phospholipids. Of these, the 
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proportion of ceramide 1, which is a carrier of linoleate and responsible for the water-barrier 
function of the skin, is significantly lower in patients with AD (Yamamoto et al. 1991). 
Therefore, the composition of sebum may also affect the fungal microbiota. 
3. Immunological aspects of Malassezia colonizaiton 
3.1 Malassezia specific IgE antibody 
Specific IgE antibodies against skin Malassezia are present in the serum of AD patients 
whereas no anti-Malassezia specific IgE antibody is found in the serum of healthy 
individuals (Sugita et al. 2001). Many studies have reported on anti-Malassezia specific IgE 
antibodies in AD patients (Zargari et al. 2003; Kato et al. 2006). Using an enzyme-linked 
immunosorbent assay (ELISA), Kato et al. (2006) quantified specific IgE antibodies against 
soluble proteins of eight Malassezia species in mechanically disrupted extracts of serum 
samples from AD patients. The level of IgE specific for M. restricta was greater than that 
against other Malassezia species (M. dermatis, M. furfur, M. globosa, M. obtusa, M. 
pachydermatis, M. slooffiae, and M. sympodialis) (Fig. 7); however, a competitive inhibition 
ELISA revealed that M. restricta contained species-specific as well as shared antigens. 
 
 
N=24 
Fig. 7. The species-specific IgE values of eight Malassezia species in sera from patients with 
atopic dermatitis determined using an ELISA. 
www.intechopen.com
 Atopic Dermatitis and Skin Fungal Microorganisms 
 
131 
The precise mechanisms by which Malassezia colonization induces IgE antibody production 
and the inflammatory cascades that lead to AD remain unclear. The presence of IgE 
antibodies has been implicated in the production of Th2-type cytokines such as interleukins 
(IL)-4, -5, -6, -10, and -13, the promotion of IgE antibody production, the differentiation of 
mast cells, and the growth, migration, and activation of eosinophils (Hamid et al. 1994; 
Leung et al. 2000; Chen et al. 2004). Keratinocytes, the major cell type in the epidermis, have 
roles in both skin structural and immunological defense (Esche et al. 2004; Albanesi et al. 
2005). Keratinocytes produce a range of proinflammatory and immune cytokines in 
response to microorganisms and/or skin damage (Grone et al. 2002; Watanabe et al. 2001). A 
recent study has demonstrated that keratinocytes secrete several Th2-type cytokines that are 
critical in the pathogenesis of AD (Ishibashi et al. 2006). Cytokine secretion profiling by 
antibody array analysis has revealed that M. globosa and M. restricta induce the secretion of 
distinct Th2-type cytokines by human keratinocytes: M. globosa induces IL-5, IL-10, and IL-
13 secretion, while M. restricta induces IL-4 secretion. These findings have been confirmed 
by cDNA microarray analysis showing that M. globosa and M. restricta upregulate the 
transcription of the IL-5 and IL-4 genes, respectively, in keratinocytes. These observations 
provide evidence of a possible relationship between Malassezia colonization and increased 
IgE production in AD. It is possible that M. globosa and M. restricta play a synergistic role 
in triggering a Th2-shifted humoral immune response in AD. Another important 
connection between Malassezia colonization and AD relates to the increased secretion of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and cutaneous T-cell-
attracting chemokine (CTACK) by keratinocytes (Ishibashi et al. 2006). Malassezia globosa is 
capable of stimulating keratinocytes to secrete GM-CSF, which primarily contributes to 
the maintenance of the chronic inflammatory process in AD by enhancing the antigen-
presenting capacity of Langerhans cells and dendritic cells (Witmer-Pack et al. 1987). 
Malassezia restricta induces the secretion of CTACK by keratinocytes. CTACK selectively 
attracts cutaneous lymphocyte antigen-positive memory T cells to inflammatory sites 
(Morales et al. 1999) and is upregulated in AD patients (Kakinuma et al. 2003). The above 
findings suggest the following possible mechanism by which Malassezia species induce an 
IgE-immune response in patients with AD: a skin barrier dysfunction facilitates skin 
penetration by colonized Malassezia, allowing interactions between Malassezia and 
epidermal Langerhans cells, dendritic cells, and keratinocytes, which subsequently 
present Malassezia antigens, thereby inducing an immune response. This may be 
augmented by keratinocyte-derived GM-CSF. Malassezia-stimulated keratinocytes 
produce Th2 cytokines, including IL-4 and IL-13, which may in turn stimulate B cells to 
undergo IgE class switching and produce Malassezia-specific IgE. In addition, 
keratinocyte-derived IL-5 may attract and locally activate eosinophils in lesions of AD. 
3.2 Malassezia allergens 
Many Malassezia allergens have been identified, including Mala f2-4, Mala s1, and Mala s5-13. 
Several researchers have attempted to produce recombinant Malassezia allergens (rMala s1 and 
rMala s5–11) for diagnostic purposes (Schmidt et al. 1997; Schmid-Grendelmeier et al. 2005, 
2006; Limacher et al. 2007) (Table 2). Recently, proteomics analysis has been applied to identify 
major allergens of M. globosa (Ishibashi et al. 2009). The IgE-reactive component of M. globosa, 
with a molecular mass of 42 kDa and designated as MGp42, has been identified by two-
dimensional immunoblotting and partially sequenced by matrix-assisted laser desorption 
ionization time of flight mass spectrometry with post-source decay of the peptide digest. The 
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full-length cDNA encoding MGp42 has been cloned and sequenced by the rapid amplification 
of cDNA ends method. MGp42 exhibits properties similar to those of heat shock protein (hsp) 
family members, and evidence indicates that MGp42 may be a cleavage product of intact 
HSP70. However, no IgE cross-reactivity has been observed between MGp42 and recombinant 
human HSP70, suggesting that the epitopes of MGp42 recognized by serum IgE of AD 
patients are masked by steric hindrance in the presence of intact HSP70 and become exposed 
as a result of conformational changes during HSP70 cleavage. 
 
Allergens Function Species Reference 
Mala s1 Unknown M. sympodialis Schmidt et al. 1997 
Mala f2 peroxisomal protein M. furfur Yasueda et al. 1998 
Mala f3 peroxisomal protein M. furfur Yasueda et al. 1998 
Mala f4 Malate dehydrogenase M. furfur Onishi et al. 1999 
Mala s5 peroxisomal protein M. sympodialis Hemmann et al. 1997 
Mala s6 Cyclophilin M. sympodialis Hemmann et al. 1997 
Mala s7 Unknown M. sympodialis Weichel et al. 2002 
Mala s8 Unknown M. sympodialis Weichel et al. 2002 
Mala s9 Unknown M. sympodialis Weichel et al. 2002 
Mala s10 Heat shock protein M. sympodialis Lindborg et al. 1999 
Mala s11 MnSOD M. sympodialis Lindborg et al. 1999 
Mala s12 GMC oxidoreductase M. sympodialis Rasool et al. 2000 
Mala s13 Thioredoxin M. sympodialis Limacher et al. 2007 
MGp42 Heat shock protein M. globosa Ishibashi et al. 2009 
Table 2. Malassezia allergens 
4. Treatment with antifungal agents 
4.1 Anti-Malassezia IgE in the serum of AD patients 
Skin prick tests positive for Malassezia antigen and specific IgE antibodies have been 
demonstrated in head and neck AD (HANAD) patients. A delayed-type hypersensitivity to 
Malassezia antigen also seems to play a role. Of 33 HANAD patients, 79% were prick-test 
positive for Malassezia antigen, but only 44% of 22 AD patients without head and neck 
involvement were prick-test positive (Kieffer et al. 1990). Rokugo et al. (1990) found that 71% of 
35 AD patients who were prick-test positive for Malassezia antigen also demonstrated delayed 
hypersensitivity to Malassezia antigen in 64% of 118 AD patients. The presence of anti-
Malassezia IgE antibody has been demonstrated in several studies (Table 3). The frequency of 
Malassezia specific IgE antibody in serum was higher in AD patients with head and neck 
dermatitis than without. For example, Bayrou et al. (2005) found IgE antibodies against 
Malassezia antigen in 100% of 106 HANAD patients, but in only 28% of 25 AD patients without 
head and neck involvement. Total IgE levels were also significantly higher in the AD group 
with head and neck dermatitis (mean, 2,823 kU/L) than without (546 kU/L). 
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Authors Patients 
Production of anti-Malassezia 
specific IgE antibodies 
Devos and Valk, 2000 HANAD 100% (n=22) 
 Non-HANAD 14% (n=22) 
Johansson et al. 2003 HANAD 55% (n=98) 
 Non-HANAD 19% (n=33) 
Jensen-Jarolim et al. 1992 HANAD 68% (n=80) 
Table 3. Malassezia IgE antibodies in sera of patient with atopic dermatitis 
There was also a significant correlation between the level of Malassezia specific IgE antibody 
and clinical severity criteria, as reflected by the SCORAD index (p < 0.0001, r2 = 0.55), 
whereas total IgE showed only a slight correlation with severity criteria (p < 0.001, r2=0.29). 
No correlation was found between age or gender, and specific or total IgE. Based on prick-
test results and specific IgE antibody levels, treatment of HANAD patients with antifungal 
agents has been recommended for the previous two decades. 
4.2 Susceptibility of Malassezia to drug treatment 
Compared with the plethora of antibacterial agents, only a small number of antifungal 
agents are available, which limits the treatment options for HANAD. Ketoconazole and 
itraconazole are highly effective in vitro (Sugita et al. 2005, Miranda et al. 2007, Sancak et al. 
2005, Velegraki et al. 2004). In a large-scale study using 125 strains of 11 Malassezia species, 
all of the Malassezia species were highly susceptible to both itraconazole and ketoconazole, 
with minimum inhibitory concentrations (MICs) ranging from 0.016 to 0.25 mg/ml; 
approximately 80% of the strains had a MIC of ≤0.03 mg/ml (Sugita et al. (2005). This 
efficacy is not specific to these species, but applies to all members of the genus Malassezia. To 
our knowledge, no resistant strain has been detected. Ketoconazole and itraconazole are 
chemically classified as azole compounds, but other azole agents, fluconazole, voriconazole, 
and terbinafine, cannot inhibit the growth of Malassezia. 
A calcineurin inhibitor, topical tacrolimus, is widely used to treat AD. This compound had 
antifungal activity against half of the known Malassezia strains, with MICs of 16–32 mg/mL 
(Sugita et al. 2005). The immunosuppressive drugs cyclosporine and tacrolimus target 
calcineurin and are also toxic to Candida albicans and Cryptococcus neoformans (Cruz et al. 
2001). A combination of either ketoconazole or itraconazole and tacrolimus had a synergistic 
effect against Malassezia strains, based on a fractional inhibitory index of 0.245 to 0.378. 
These observations follow earlier reports on the effectiveness of a combination of tacrolimus 
and fluconazole against C. albicans and C. neoformans strains. The combination of topical 
tacrolimus and an azole agent can simultaneously treat AD and reduce the number of 
exacerbating Malassezia cells colonizing the skin surface. Although the synergistic 
mechanism of this combination is not known, Maesaki et al. (1998) demonstrated that 
tacrolimus increases the intracellular concentration of the azole agent in C. albicans. This 
observation may provide the basis for future clinical trials of these agents aimed at reducing 
the number of Malassezia cells colonizing the skin of AD patients (more details are provided 
in the following section). 
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Authors Drug Study design
Number of 
patients 
Dosage 
Bäck et al. 
1995 
Ketoconazole
Open-label 
study 
20 AD patients 
with positive 
RAST to 
Malassezia  
200 mg daily for 2 months and 
200 mg twice weekly for 
further 3 months. 
Broberg and 
Faergemann, 
1995 
Ketoconazole 
shampoo 
Randomized 
double-blind 
placebo-
controlled 
study 
53 HANAD 
patients 
Group A: miconazole-
hydrocortisone cream and 
ketoconazole shampoo for 6 
weeks 
    
Group B: hydrocortisone cream 
and placebo shampoo for 6 
weeks 
Bäck and 
Bartosik, 
2001 
Ketoconazole
Randomized 
double-blind 
placebo-
controlled 
study 
29 HANAD 
patients with 
specific IgE 
antibodies to 
Malassezia 
Group A: 200 mg ketoconazole 
daily for 3 months 
    Group B: placebo for 3 months 
Ikezawa  
et al. 2004 
Itraconazole 
Randomized 
double-blind 
crossover 
study 
34 AD patients 
with positive 
RAST to 
Malassezia 
Group A: 100 mg daily of 
itraconazole and lactobacillus 
preparation  for 8 weeks and 
lactobacillus preparation alone 
for further 8 weeks 
    
Group B: Lactobacillus 
preparation alone for 8 weeks 
and 100 mg daily of itraconazole 
and lactobacillus preparation 
for additionally 8 weeks 
Svejgaard  
et al. 2005 
Itraconazole 
Randomized 
double-blind 
placebo-
controlled 
study 
53 HANAD 
patients 
Group A: 200 mg itraconazole 
for 7 days 
    
Group B: 400 mg itraconazole 
for 7 days 
    Group C: placebo 
Table 4. Treatment for ketoconazole or itraconazole in HANAD patients 
4.3 Ketoconazole and itraconazole in AD treatment (Table 4) 
A relationship between Malassezia and AD was first suggested by Clemmensen and Hjorth 
(1983), who demonstrated that oral ketoconazole was efficacious in adult HANAD patients 
with positive prick tests for Malassezia. A study of 20 AD patients with positive 
radioallergosorbent test results for Malassezia showed that treatment with oral ketoconazole 
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improved clinical scores and reduced the levels of Malassezia specific IgE, particularly in the 
head and neck area (Bäck et al. 1995). However, in a double-blind study with 53 HANAD 
patients, no difference in the clinical score was detected between those treated with 
miconazole-hydrocortisone cream and ketoconazole shampoo and those treated with 
hydrocortisone cream and placebo shampoo, although the ketoconazole group showed 
decreased Malassezia colonization (Broberg and Faergemann 1995). In another randomized 
double-blind placebo-controlled study comparing treatment with 200 mg ketoconazole daily 
versus placebo for 3 months in 29 HANAD patients with specific IgE antibodies to 
Malassezia, the clinical score decreased in both groups, and the improvement was correlated 
with the use of topical steroids in the control group, but not in the ketoconazole group (Bäck 
and Bartosik 2001). 
A number of studies have also been conducted with itraconazole. In one study, 53 HANAD 
patients were divided into three groups that received 200 mg itraconazole, 400 mg 
itraconazole, or placebo daily (Svejgaard et al. 2004). The study included a 7-day treatment 
period and a follow-up period of 105 days. At days 7 and 14, a significant improvement was 
observed in the SCORAD of the head and neck area in the groups given 400 and 200 mg 
itraconazole daily. At day 14, a comparison among all three groups showed a significant 
improvement in the SCORAD of the head and neck area in the 200 mg itraconazole group 
compared with the placebo group. A randomized double-blind crossover study was also 
conducted (Ikezawa et al. 2004). One group was treated with a combination of 
itraconazole (100 mg daily) plus a conventional Lactobacillus preparation for 8 weeks, 
followed by the Lactobacillus preparation alone for 8 weeks. The other group received the 
Lactobacillus preparation alone for 8 weeks, followed by itraconazole (100 mg daily) plus 
Lactobacillus for 8 weeks. In both groups, a decrease in the dose or strength of concomitant 
topical steroids was observed at the end of the treatment course with itraconazole, and 
improvements in the eosinophil count, serum IgE, and fungi-specific IgE were found after 
the administration of itraconazole. 
Itraconazole appears to be a promising treatment option for HANAD patients who do not 
respond to conventional therapeutic approaches. To optimize the selection of patients most 
likely to respond to itraconazole treatment, the levels of Malassezia colonization of the skin 
and specific IgE antibody should be evaluated. 
5. Acknowledgment 
This study was supported in part by a research grant from the Japan Society for the 
Promotion of Science (TS), a research grant for “High-Tech Research Center Project” from 
the Ministry of Education, Culture, Sports, Science, and Technology (TS). 
6. References 
Albanesi C, Scarponi C, Giustizieri ML, Girolomoni G. 2005, Keratinocytes in inflammatory 
skin diseases. Curr Drug Targets Inflamm Allergy. 4, 329-334. 
Amaya M, Tajima M, Okubo Y, Sugita T, Nishikawa A, Tsuboi R. 2007, Molecular analysis of 
Malassezia microflora in the lesional skin of psoriasis patients. J Dermatol. 34, 619-624. 
Ashbee HR. 2007, Update on the genus Malassezia. Med Mycol. 45, 287-303.  
www.intechopen.com
 Atopic Dermatitis – Disease Etiology and Clinical Management 
 
136 
Bäck O, Scheynius A, Johansson SG. 1995, Ketoconazole in atopic dermatitis: therapeutic 
response is correlated with decrease in serum IgE. Arch Dermatol Res. 287, 448-451. 
Bäck O, Bartosik J. 2001, Systemic ketoconazole for yeast allergic patients with atopic 
dermatitis. J Eur Acad Dermatol Venereol 15, 34-38.  
Bayrou O, Pecquet C, Flahault A, Artigou C, Abuaf N, Leynadier F. 2005, Head and neck 
atopic dermatitis and malassezia-furfur-specific IgE antibodies. Dermatology 211, 
107-113. 
Broberg A, Faergemann J. 1995, Topical antimycotic treatment of atopic dermatitis in the 
head/neck area. A double-blind randomised study. Acta Derm Venereol. 75, 46-49. 
Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar BS, Chan LS. 2004, Early up-
regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis 
model. Clin Exp Immunol. 138, 375-387. 
Clemmensen OJ, Hjorth N. 1983, Treatment of dermatitis of head and neck with 
ketoconazole in patients with type 1 sensitivity to Pityrosporum orbiculare. Semin. 
Dermatol. 2, 26-29. 
Cruz M C, A L Goldstein, J Blankenship, M Del Poeta, J R Perfect, J H McCusker, Y L 
Bennani, M E Cardenas, J Heitman. 2001. Rapamycin and less immunosuppressive 
analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-
dependent inhibition of TOR. Antimicrob. Agents Chemother. 45, 3162-3170. 
Devos SA, van der Valk PG. 2000, The relevance of skin prick tests for Pityrosporum ovale in 
patients with head and neck dermatitis. Allergy. 55, 1056-1058. 
Esche C, de Benedetto A, Beck LA. 2004, Keratinocytes in atopic dermatitis. inflammatory 
signals. Curr Allergy Asthma Rep. 4, 276-284.  
Grone, A. 2002, Keratinocytes and cytokines. Vet Immunol Immunopathol. 88, 1-12.   
Guého-Kellermann E, Boekhout T, Begerow D. 2010, Biodiversity, Phylogeny and 
Ultrastructure. In Malassezia and the skin. Edited by Boekhout, Guého-Kellermann 
E, Mayser P, and Velegraki A, pp. 17-64, Springer, 2010. 
Gupta AK, Kohli Y, Summerbell RC, Faergemann J. 2001, Quantitative culture of Malassezia 
species from different body sites of individuals with or without dermatoses. Med 
Mycol. 39, 243-251. 
Gupta AK, Batra R, Bluhm R, Boekhout T, Dawson TL Jr. 2004, Skin diseases associated with 
Malassezia species. J Am Acad Dermatol. 51, 785-798. 
Hamid Q, Boguniewicz M, Leung DY. 1994, Differential in situ cytokine gene expression in 
acute versus chronic atopic dermatitis. J Clin Invest. 94, 870-876.   
Hemmann S, Blaser K, Crameri R. 1997, Allergens of Aspergillus fumigatus and Candida 
boidinii share IgE-binding epitopes. Am J Respir Crit Care Med. 156, 1956-1962. 
Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. 1999, Comparative study of 
staphylococci from the skin of atopic dermatitis patients and from healthy subjects. 
Int J Dermatol. 38, 265-269. 
Hoeger PH, Lenz W, Boutonnier A, Fournier JM. 1992, Staphylococcal skin colonization in 
children with atopic dermatitis: prevalence, persistence, and transmission of 
toxigenic and nontoxigenic strains. J Infect Dis. 165, 1064-1068. 
Howell MD. 2007, The role of human beta defensins and cathelicidins in atopic dermatitis. 
Curr Opin Allergy Clin Immunol. 7, 413-417.  
www.intechopen.com
 Atopic Dermatitis and Skin Fungal Microorganisms 
 
137 
Ikezawa Z, Kondo M, Okajima M, Nishimura Y, Kono M. 2004, Clinical usefulness of oral 
itraconazole, an antimycotic drug, for refractory atopic dermatitis. Eur J Dermatol. 
14, 400-406. 
Ishibashi Y Sugita T Nishikawa A. 2006, Cytokine secretion profile of human keratinocytes 
exposed to Malassezia yeasts. FEMS Immunol Med Microbiol. 48, 400-409. 
Ishibashi Y, Kato H, Asahi Y, Sugita T, Nishikawa A. 2009, Identification of the major allergen 
of Malassezia globosa relevant for atopic dermatitis. J Dermatol. Sci. 55, 185-192. 
Jensen-Jarolim E, Poulsen LK, With H, Kieffer M, Ottevanger V, Stahl Skov P.  1992, Atopic 
dermatitis of the face, scalp, and neck: type I reaction to the yeast Pityrosporum 
ovale? J Allergy Clin Immunol. 89, 44-51. 
Johansson C, Sandström MH, Bartosik J, Särnhult T, Christiansen J, Zargari A, Bäck O, 
Wahlgren CF, Faergemann J, Scheynius A, Tengvall Linder M. 2003, Atopy patch 
test reactions to Malassezia allergens differentiate subgroups of atopic dermatitis 
patients. Br J Dermatol 148, 479-488. 
Kaga M, Sugita T, Nishikawa A, Wada Y, Hiruma M, Ikeda S. 2011, Molecular analysis of 
the cutaneous Malassezia microbiota from the skin of patients with atopic dermatitis 
of different severities. Mycoses 54, e24-28. 
Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Asano N, Mitsui H, Tada Y, Wakugawa M, 
Watanabe T, Torii H, Komine M, Asahina A, Nakamura K, Tamaki K. 2003, 
Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients 
with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol. 111, 592-597.   
Kaneko T, Makimura K, Abe M, Shiota R, Nakamura Y, Kano R, Hasegawa A, Sugita T, 
Shibuya S, Watanabe S, Yamaguchi H, Abe S, Okamura N. 2007, Revised culture-
based system for identification of Malassezia species. J Clin Microbiol. 45, 3737-3742. 
Kato H, Sugita T, Ishibashi Y, Nishikawa A. 2006, Detection and quantification of specific IgE 
antibodies against eight Malassezia species in sera of patients with atopic dermatitis 
by using an enzyme-linked immunosorbent assay. Microbiol Immunol. 50, 851-856. 
Kieffer M, Bergbrant I-M, Faergeman J, Jemec GBE, Ottevanger V, Skov PS, Svejgaard E. 1990, 
Immune reactions to Pityrosporum ovale in adult patients with atopic and 
seborrhoeic dermatitis. J. Am. Acad. Dermatol. 22, 739-742. 
Leung DY. 2000, Atopic dermatitis. new insights and opportunities for therapeutic 
intervention. J Allergy Clin Immunol. 105, 860-876. 
Limacher A, Glaser AG, Meier C, Schmid-Grendelmeier P, Zeller S, Scapozza L, Crameri R. 
2007, Cross-reactivity and 1.4-A crystal structure of Malassezia sympodialis thioredoxin 
(Mala s 13), a member of a new pan-allergen family. J Immunol 178, 389-396. 
Lindborg M, Magnusson CG, Zargari A, Schmidt M, Scheynius A, Crameri R, Whitley P. 
1999, Selective cloning of allergens from the skin colonizing yeast Malassezia furfur 
by phage surface display technology. J Invest Dermatol 113, 156-161. 
Maesaki S, P Marichal, M A Hossain, D Sanglard, H Vanden Bossche, S Kohno. 1998, 
Synergic effects of tactolimus and azole antifungal agents against azole-resistant 
Candida albican strains. J. Antimicrob. Chemother. 42, 747-753. 
Miranda KC, de Araujo CR, Costa CR, Passos XS, de Fátima Lisboa Fernandes O, do Rosário 
Rodrigues Silva M. 2007, Antifungal activities of azole agents against the 
Malassezia species. Int J Antimicrob Agents. 29, 281-284.  
www.intechopen.com
 Atopic Dermatitis – Disease Etiology and Clinical Management 
 
138 
Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, Orozco R, Copeland NG, 
Jenkins NA, McEvoy LM, Zlotnik A. 1999, CTACK, a skin-associated chemokine 
that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 96, 
14470-14475. 
Morishita N, Sei Y, Sugita T. 2006, Molecular analysis of malassezia microflora from patients 
with pityriasis versicolor. Mycopathologia 161, 61-65. 
Nakabayashi A, Sei Y, Guillot J. 2000, Identification of Malassezia species isolated from 
patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and 
normal subjects. Med Mycol. 38, 337-341. 
Onishi Y, Kuroda M, Yasueda H, Saito A, Sono-Koyama E, Tunasawa S, Hashida-Okado T, 
Yagihara T, Uchida K, Yamaguchi H, Akiyama K, Kato I, Takesako K. 1999, Two-
dimensional electrophoresis of Malassezia allergens for atopic dermatitis and 
isolation of Mal f 4 homologs with mitochondrial malate dehydrogenase. Eur J 
Biochem. 261, 148-154. 
Rasool O, Zargari A, Almqvist J, Eshaghi H, Whitley P, Scheynius A. 2000, Cloning, 
characterization and expression of complete coding sequences of three IgE binding 
Malassezia furfur allergens, Mal f 7, Mal f 8 and Mal f 9. Eur J Biochem 267, 4355-4361. 
Rokugo M, Tagami H, Usuba Y, Tomita Y. 1990, Contact sensitivity to Pityrosporum ovale in 
patients with an atopic dermatitis. Arch. Dermatol. 126, 627-634. 
Sancak B, Ayhan M, Karaduman A, Arikan S. 2005, In vitro activity of ketoconazole, 
itraconazole and terbinafine against Malassezia strains isolated from neonates. 
Mikrobiyol Bul. 39, 301-308. Turkish. 
Sandström Falk MH, Tengvall Linder M, Johansson C, Bartosik J, Bäck O, Särnhult T, 
Wahlgren CF, Scheynius A, Faergemann J. 2005, The prevalence of Malassezia yeasts 
in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta 
Derm Venereol. 85, 17-23. 
Schmidt M, Zargari A, Holt P, Lindbom L, Hellman U, Whitley P, van der Ploeg I, Härfast B, 
Scheynius A. 1997, The complete cDNA sequence and expression of the first major 
allergenic protein of Malassezia furfur, Mal f 1. Eur J Biochem 246, 181-185. 
Schmid-Grendelmeier P, Flückiger S, Disch R, Trautmann A, Wüthrich B, Blaser K, 
Scheynius A, Crameri R. 2005, IgE-mediated and T cell-mediated autoimmunity 
against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin 
Immunol 115, 1068-1075.  
Schmid-Grendelmeier P, Scheynius A, Crameri R. 2006, The role of sensitization to 
Malassezia sympodialis in atopic eczema. Chem Immunol Allergy 91, 98-109.  
Seidenari S, Giusti G. 1995, Objective assessment of the skin of children affected by atopic 
dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically 
uninvolved skin. Acta Derm Venereol. 75, 429-433. 
Sugita T, Suto H, Unno T, Tsuboi R, Ogawa H, Shinoda T, Nishikawa A. 2001, Molecular 
analysis of Malassezia microflora on the skin of atopic dermatitis patients and 
healthy subjects. J Clin Microbiol. 39, 3486-3490. 
Sugita T, Kodama M, Saito M, Ito T, Kato Y, Tsuboi R, Nishikawa A. 2003, Sequence 
diversity of the intergenic spacer region of the rRNA gene of Malassezia globosa 
colonizing the skin of patients with atopic dermatitis and healthy individuals. J Clin 
Microbiol. 41, 3022-3027. 
www.intechopen.com
 Atopic Dermatitis and Skin Fungal Microorganisms 
 
139 
Sugita T, Tajima M, Amaya M, Tsuboi R, Nishikawa A. 2004, Genotype analysis of 
Malassezia restricta as the major cutaneous flora in patients with atopic dermatitis 
and healthy subjects. Microbiol Immunol. 48, 755-759. 
Sugita T, Tajima M, Ito T, Saito M, Tsuboi R, Nishikawa A. 2005, Antifungal activities of 
tacrolimus and azole agents against the eleven currently accepted Malassezia 
species. J Clin Microbiol. 43, 2824-2829. 
Sugita T, Tajima M, Tsubuku H, Tsuboi R, Nishikawa A. 2006a, Quantitative analysis of 
cutaneous Malassezia in atopic dermatitis patients using real-time PCR. Microbiol 
Immunol. 50, 549-552. 
Sugita T, Boekhout T, Velegraki A, Guillot J, Hadina S, Cabanes FJ. 2010, Epidemiology of 
Malassezia-related skin diseases. In Malassezia and the skin. Edited by Boekhout, 
Guého-Kellermann E, Mayser P, and Velegraki A, pp. 65-120, Springer, 2010. 
Sugita T, Zhang E, Miyamoto M, Tajima M, Tsuboi R, Nishikawa A. 2011, Chapter 73 
Malassezia, In Molecular Detection of Human Fungal Pathogens. Edited by 
Dongyou Liu, Taylor & Francis Group. 631-638. 
Svejgaard E, Larsen PØ, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. 2004, 
Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg 
daily for 1 week with placebo. J Eur Acad Dermatol Venereol. 18, 445-449. 
Tajima M, Sugita T, Nishikawa A, Tsuboi R. 2008, Molecular analysis of Malassezia 
microflora in seborrheic dermatitis patients: comparison with other diseases and 
healthy subjects. J Invest Dermatol. 128, 345-351. 
Takahata Y, Sugita T, Hiruma M, Muto M. 2007a, Quantitative analysis of Malassezia in the 
scale of patients with psoriasis using a real-time polymerase chain reaction assay. 
Br J Dermatol. 157, 670-673. 
Takahata Y, Sugita T, Kato H, Nishikawa A, Hiruma M, Muto M. 2007b, Cutaneous 
Malassezia flora in atopic dermatitis differs between adults and children. Br J 
Dermatol. 157, 1178-1182.  
Velegraki A, Alexopoulos EC, Kritikou S, Gaitanis G. 2004, Use of fatty acid RPMI 1640 
media for testing susceptibilities of eight Malassezia species to the new triazole 
posaconazole and to six established antifungal agents by a modified NCCLS M27-
A2 microdilution method and Etest. J Clin Microbiol. 42, 3589-3593.  
Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. 2001, The effects of Malassezia yeasts 
on cytokine production by human keratinocytes. J Invest Dermatol. 116, 769-773.  
Weichel M, Fluckiger S, Crameri R. 2002. Molecular characterization of mould allergens 
involved in respiratory complications. Rencet Res devel Resp Critical Care Med. 2, 
29-45. 
Witmer-Pack MD, Olivier W, Vaiinsky J. 1987, Granulocyte-macrophage colony-stimulating 
factor is essential for the viability and function of cultured murine epidermal 
Langerhans cells. J Exp Med. 166, 1484-1498. 
Xu J, Saunders CW, Hu P, Grant RA, Boekhout T, Kuramae EE, Kronstad JW, Deangelis YM, 
Reeder NL, Johnstone KR, Leland M, Fieno AM, Begley WM, Sun Y, Lacey MP, 
Chaudhary T, Keough T, Chu L, Sears R, Yuan B, Dawson TL Jr. 2007, Dandruff-
associated Malassezia genomes reveal convergent and divergent virulence traits 
shared with plant and human fungal pathogens. Proc Natl Acad Sci U S A. 104, 
18730-18735.  
www.intechopen.com
 Atopic Dermatitis – Disease Etiology and Clinical Management 
 
140 
Yamamoto A, Serizawa S, Ito M, Sato Y. 1991, Stratum corneum lipid abnormalities in atopic 
dermatitis. Arch Dermatol Res. 283, 219-223. 
Yasueda H, Hashida-Okado T, Saito A, Uchida K, Kuroda M, Onishi Y, Takahashi K, 
Yamaguchi H, Takesako K, Akiyama K. 1998. Identification and cloning of two 
novel allergens from the lipophilic yeast, Malassezia furfur. Biochem Biophys Res 
Commun. 248, 240-244. 
Zargari A, Midgley G, Bäck O, Johansson SG, Scheynius A. 2003, IgE-reactivity to seven 
Malassezia species. Allergy 58, 306-311. 
Zhang E, Tanaka T, Tajima M, Tsuboi R, Nishikawa A, Sugita T. 2011, Characterization of the 
skin fungal microbiota in patients with atopic dermatitis and healthy subjects. 
Microbiol Immunol Jun 24. doi: 10.1111/j.1348-0421.2011.00364.x. [Epub ahead of print] 
www.intechopen.com
Atopic Dermatitis - Disease Etiology and Clinical Management
Edited by Dr. Jorge Esparza-Gordillo
ISBN 978-953-51-0110-9
Hard cover, 414 pages
Publisher InTech
Published online 22, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Atopic Dermatitis is a common disease characterized by inflamed, itching and dry skin. This relapsing allergic
disorder has complex etiology and shows a remarkably high clinical heterogeneity which complicates the
diagnosis and clinical management. This book is divided into 4 sections. The first section (Disease Etiology)
describes some of the physiological mechanisms underlying Atopic Dermatitis, including alterations in the
immune system and the skin-barrier function. The important role of host-microorganism interactions on the
pathophysiology of Atopic Dermatitis is discussed in the second section (Microorganisms in Atopic Dermatitis).
An overview of the clinical diagnostic criteria and the disease management protocols commonly used is given
in the third section (Diagnosis and Clinical Management). The last section (New Treatments) describes new
therapeutic approaches that are not widely used but are currently being studied due to preliminary evidence
showing a clinical benefit for Atopic Dermatitis.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Takashi Sugita, Enshi Zhang, Takafumi Tanaka, Mami Tajima, Ryoji Tsuboi, Yoshio Ishibashi, Akemi
Nishikawa (2012). Atopic Dermatitis and Skin Fungal Microorganisms, Atopic Dermatitis - Disease Etiology and
Clinical Management, Dr. Jorge Esparza-Gordillo (Ed.), ISBN: 978-953-51-0110-9, InTech, Available from:
http://www.intechopen.com/books/atopic-dermatitis-disease-etiology-and-clinical-management/atopic-
dermatitis-and-skin-fungal-microorganisms
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
